Snowden Capital Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.83M | Buy |
20,323
+608
| +3% | +$85.1K | 0.08% | 263 |
|
|
2025
Q4 | $2.42M | Buy |
19,715
+1,945
| +11% | +$236K | 0.06% | 291 |
|
|
2025
Q3 | $1.97M | Buy |
17,770
+534
| +3% | +$60.7K | 0.05% | 327 |
|
|
2025
Q2 | $1.91M | Sell |
17,236
-2,817
| -14% | -$300K | 0.06% | 326 |
|
|
2025
Q1 | $2.25M | Sell |
20,053
-1,895
| -9% | -$196K | 0.07% | 272 |
|
|
2024
Q4 | $2.03M | Sell |
21,948
-45,195
| -67% | -$4.07M | 0.06% | 300 |
|
|
2024
Q3 | $5.63M | Sell |
67,143
-40,802
| -38% | -$3.11M | 0.17% | 143 |
|
|
2024
Q2 | $7.41M | Buy |
107,945
+12,615
| +13% | +$842K | 0.22% | 106 |
|
|
2024
Q1 | $6.98M | Buy |
95,330
+10,582
| +12% | +$814K | 0.22% | 105 |
|
|
2023
Q4 | $6.87M | Buy |
84,748
+247
| +0.3% | +$19.2K | 0.26% | 95 |
|
|
2023
Q3 | $6.33M | Sell |
84,501
-4,722
| -5% | -$363K | 0.27% | 87 |
|
|
2023
Q2 | $6.88M | Sell |
89,223
-1,186
| -1% | -$94.6K | 0.25% | 97 |
|
|
2023
Q1 | $7.5M | Sell |
90,409
-7,405
| -8% | -$613K | 0.29% | 75 |
|
|
2022
Q4 | $8.4M | Sell |
97,814
-1,387
| -1% | -$110K | 0.35% | 52 |
|
|
2022
Q3 | $6.12M | Buy |
99,201
+367
| +0.4% | +$23.1K | 0.28% | 82 |
|
|
2022
Q2 | $6.11M | Buy |
98,834
+4,551
| +5% | +$282K | 0.27% | 86 |
|
|
2022
Q1 | $5.61M | Buy |
94,283
+15,479
| +20% | +$989K | 0.22% | 113 |
|
|
2021
Q4 | $5.72M | Buy |
78,804
+67,834
| +618% | +$4.67M | 0.29% | 91 |
|
|
2021
Q3 | $766K | Buy |
10,970
+242
| +2% | +$17K | 0.04% | 423 |
|
|
2021
Q2 | $739K | Buy |
10,728
+5,227
| +95% | +$349K | 0.04% | 442 |
|
|
2021
Q1 | $356K | Buy |
5,501
+1,302
| +31% | +$84K | 0.02% | 575 |
|
|
2020
Q4 | $245K | Sell |
4,199
-6,993
| -62% | -$422K | 0.02% | 581 |
|
|
2020
Q3 | $707K | Buy |
11,192
+1,141
| +11% | +$79.1K | 0.06% | 318 |
|
|
2020
Q2 | $773K | Buy |
10,051
+4,649
| +86% | +$356K | 0.07% | 295 |
|
|
2020
Q1 | $404K | Buy |
5,402
+1,000
| +23% | +$69.1K | 0.04% | 380 |
|
|
2019
Q4 | $286K | Buy |
4,402
+93
| +2% | +$6.06K | 0.03% | 494 |
|
|
2019
Q3 | $273K | Sell |
4,309
-39
| -0.9% | -$2.55K | 0.03% | 441 |
|
|
2019
Q2 | $294K | Sell |
4,348
-211
| -5% | -$13.9K | 0.03% | 415 |
|
|
2019
Q1 | $296K | Sell |
4,559
-356
| -7% | -$23.7K | 0.03% | 407 |
|
|
2018
Q4 | $307K | Buy |
4,915
+14
| +0.3% | +$979 | 0.04% | 376 |
|
|
2018
Q3 | $378K | Buy |
+4,901
| New | +$370K | 0.04% | 358 |
|
|
2016
Q3 | – | Sell |
-11,511
| Closed | -$960K | – | 287 |
|
|
2016
Q2 | $960K | Sell |
11,511
-11,238
| -49% | -$997K | 0.29% | 129 |
|
|
2016
Q1 | $2.09M | Buy |
+22,749
| New | +$2.05M | 0.71% | 35 |
|
Other funds holding GILD
VCM
VPM
Snowden Capital Advisors's GILD Position: Q1 2026 in Review
Snowden Capital Advisors increased its Gilead Sciences (GILD) stake by 3.1% in Q1 2026, buying an estimated $85.1K and bringing the position to 20,323 shares worth $2.83M. The position accounts for 0.08% of the portfolio, ranked #263.
Snowden Capital Advisors first reported a position in GILD in Q1 2016 and has held it in 33 quarters since. The position peaked at $8.4M in Q4 2022. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Snowden Capital Advisors held 20,323 shares of Gilead Sciences worth $2.83M as of Q1 2026.
- Snowden Capital Advisors bought 608 Gilead Sciences shares in Q1 2026, an estimated $85.1K.
- Gilead Sciences made up 0.08% of Snowden Capital Advisors's portfolio in Q1 2026, its #263 holding.
- Snowden Capital Advisors first reported a position in Gilead Sciences in Q1 2016 and has held it in 33 quarters since.
- Snowden Capital Advisors's Gilead Sciences position peaked at $8.4M in Q4 2022.
- 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.